glp 1 vial Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity particularly those who have not had success with lifestyle modifications alone GLP-1 VIAL (10MG)

New York City, NY, Dec

But a side effect quickly stole the spotlight: People taking GLP-1s started losing significant amounts of weight

Since its release, Health Canada has expanded Wegovys approval to include cardiovascular risk reduction in adults with established heart disease

Kidney and liver functions naturally decline as people age, affecting how their bodies handle medications, so that needs to be monitored closely in older adults

It is available as monotherapy in both subcutaneous as well as oral dosage form (first approved oral GLP-1 receptor agonist)

The theoretical concerns centre on the potential for these large peptide molecules to affect infant growth, glucose metabolism, or gastrointestinal function, though the extent of oral bioavailability following ingestion in breast milk is uncertain